Context Therapeutics Inc.
+1.6% · 90d
$2.23
-0.04 (-1.55%)
News
(1)April 2026
Context Therapeutics Inc. — 8-K Filing
CNTXContext Therapeutics Inc.
# 🧾 What This Document Is This is a press release attached to an 8-K filing, which is a report of major events that shareholders should know about. The news here is that the U.S. Food and Drug Administration (FDA) has granted "Fast Track Designation" to Context Therapeutics' drug, CTIM-76. # 🏢 Wh
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%